Failla Michelle D, Myrga John M, Ricker Joseph H, Dixon C Edward, Conley Yvette P, Wagner Amy K
Center for Neuroscience (Drs Failla, Dixon, and Wagner), Department of Physical Medicine and Rehabilitation, School of Medicine (Drs Failla, Dixon, and Wagner and Mr Myrga), and Department of Neurological Surgery, School of Medicine (Dr Dixon), Department of Human Genetics, School of Public Health (Dr Conley), Department of Health Promotion & Development, School of Nursing (Dr Conley), and Safar Center for Resuscitation Research (Drs Wagner and Dixon), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Rehabilitation Medicine, New York University, School of Medicine, New York (Dr Ricker); and Pittsburgh VA Healthcare System, Pittsburgh, Pennsylvania (Dr Dixon).
J Head Trauma Rehabil. 2015 Nov-Dec;30(6):E54-66. doi: 10.1097/HTR.0000000000000118.
As dopamine neurotransmission impacts cognition, we hypothesized that variants in the linked dopamine D2 receptor (DRD2) and ankyrin repeat and kinase domain (ANKK1) genes might account for some individual variability in cognitive recovery following traumatic brain injury (TBI).
Prospective cohort of 108 survivors of severe TBI, recruited consecutively from a level 1 trauma center.
We examined relationships between DRD2 genetic variation and functional recovery at 6 and 12 months post-TBI.
Cognitive performance was evaluated using 8 neuropsychological tests targeting different cognitive domains. An overall cognitive composite was developed using normative data. We also assessed functional cognition, depression status, and global outcome. Subjects were genotyped for 6 DRD2 tagging single-nucleotide polymorphisms and Taq1A within ANKK1.
ANKK1 Taq1A heterozygotes performed better than homozygotes across several cognitive domains at both time points postinjury. When adjusting for age, Glasgow Coma Scale score, and education, the Taq1A (ANKK1) and rs6279 (DRD2) variants were associated with overall composite scores at 6 months post-TBI (P = .0453 and P = .0452, respectively). At 12 months, only Taq1A remained a significant genetic predictor of cognition (P = .0128). Following multiple-comparisons correction, there were no significant associations between examined genetic variants and functional cognition, depression status, and global outcome.
These data suggest that genetic variation within DRD2 influences cognitive recovery post-TBI. Understanding genetic influences on dopaminergic systems post-TBI may impact current treatment paradigms.
由于多巴胺神经传递会影响认知,我们推测,与多巴胺D2受体(DRD2)及锚蛋白重复序列和激酶结构域(ANKK1)基因相关的变异可能是创伤性脑损伤(TBI)后认知恢复个体差异的原因之一。
从一级创伤中心连续招募的108名重度TBI幸存者的前瞻性队列。
我们研究了TBI后6个月和12个月时DRD2基因变异与功能恢复之间的关系。
使用针对不同认知领域的8项神经心理学测试评估认知表现。利用标准化数据制定了一个总体认知综合指标。我们还评估了功能性认知、抑郁状态和整体结果。对受试者进行6个DRD2标签单核苷酸多态性及ANKK1内Taq1A的基因分型。
ANKK1 Taq1A杂合子在损伤后两个时间点的几个认知领域的表现均优于纯合子。在调整年龄、格拉斯哥昏迷量表评分和教育程度后,Taq1A(ANKK1)和rs6279(DRD2)变异与TBI后6个月时的总体综合评分相关(分别为P = 0.0453和P = 0.0452)。在12个月时,只有Taq1A仍然是认知的显著基因预测指标(P = 0.0128)。经过多重比较校正后,所检测的基因变异与功能性认知、抑郁状态和整体结果之间无显著关联。
这些数据表明,DRD2内的基因变异会影响TBI后的认知恢复。了解TBI后多巴胺能系统的遗传影响可能会影响当前的治疗模式。